New biologic therapy for systemic lupus erythematosus.

Abstract

Systemic lupus erythematosus (SLE) is a heterogenous multi-systemic autoimmune disease that is associated with considerable morbidity and mortality. Rituximab is one of the earliest biologic therapies used in SLE. It performed well in off-label studies but failed to demonstrate efficacy in randomised controlled trials. Abatacept is a biologic developed for inflammatory arthritis but has shown promise in SLE. Belimumab is the first biologically approved therapy in fifty years for treatment of SLE. The development of biological therapies for SLE parallels the increasing understanding of the immunopathogenesis of SLE and looks promising. New drugs in development are those targeting the co-stimulatory modulation, cytokines and the B and T cells. Of interest are epratuzumab, the interferon antagonists and peptide-based therapies.

• Authors: Hui Jen Ding, Caroline Gordon
• Journal: Current opinion in pharmacology (Curr Opin Pharmacol) Vol. 13 Issue 3 Pg. 405-12 (Jun 2013) ISSN: 1471-4973 [Electronic] England
• PMID: 23664092 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2013 Elsevier Ltd. All rights reserved.

Chemical References

• Antibodies, Monoclonal
• Cytokines
• Immunosuppressive Agents

Topics

• Animals
• Antibodies, Monoclonal (therapeutic use)
• Biological Therapy
• Cytokines (immunology)
• Humans
• Immunosuppressive Agents (therapeutic use)
• Lupus Erythematosus, Systemic (drug therapy, immunology)
• T-Lymphocytes (immunology)